Enovis (NYSE:ENOV) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Enovis (NYSE:ENOV) from a hold rating to a buy rating in a report published on Monday.

Several other research analysts have also issued reports on the company. BTIG Research boosted their target price on Enovis from $41.00 to $43.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Needham & Company LLC increased their price target on Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Wells Fargo & Company raised Enovis to a “strong-buy” rating in a research note on Wednesday, March 18th. Zacks Research upgraded Enovis from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 4th. Finally, Evercore reaffirmed an “outperform” rating on shares of Enovis in a research report on Monday, January 12th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Enovis presently has a consensus rating of “Buy” and an average price target of $47.43.

Enovis Trading Up 2.6%

ENOV stock opened at $23.34 on Monday. Enovis has a twelve month low of $21.00 and a twelve month high of $37.85. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -1.13 and a beta of 1.47. The company has a quick ratio of 1.04, a current ratio of 2.02 and a debt-to-equity ratio of 0.85. The firm’s fifty day simple moving average is $22.97 and its two-hundred day simple moving average is $27.02.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.14. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The firm had revenue of $575.76 million during the quarter, compared to analyst estimates of $584.30 million. During the same quarter last year, the business earned $0.98 EPS. The business’s revenue was up 2.6% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, analysts anticipate that Enovis will post 2.79 earnings per share for the current year.

Insider Activity at Enovis

In related news, insider Oliver Engert bought 1,000 shares of Enovis stock in a transaction dated Friday, February 27th. The shares were acquired at an average cost of $25.50 per share, with a total value of $25,500.00. Following the completion of the transaction, the insider owned 43,640 shares in the company, valued at $1,112,820. The trade was a 2.35% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have purchased 5,000 shares of company stock worth $121,983 over the last 90 days. Company insiders own 2.70% of the company’s stock.

Institutional Trading of Enovis

A number of large investors have recently modified their holdings of ENOV. McIlrath & Eck LLC increased its holdings in Enovis by 6.9% during the 3rd quarter. McIlrath & Eck LLC now owns 5,517 shares of the company’s stock worth $167,000 after purchasing an additional 357 shares during the period. Farther Finance Advisors LLC lifted its holdings in shares of Enovis by 42.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock worth $37,000 after buying an additional 367 shares during the period. Amalgamated Bank grew its position in shares of Enovis by 3.6% during the 3rd quarter. Amalgamated Bank now owns 16,793 shares of the company’s stock worth $509,000 after buying an additional 585 shares in the last quarter. Heritage Family Offices LLP grew its position in shares of Enovis by 8.9% during the 3rd quarter. Heritage Family Offices LLP now owns 7,598 shares of the company’s stock worth $231,000 after buying an additional 620 shares in the last quarter. Finally, California State Teachers Retirement System increased its stake in shares of Enovis by 1.2% during the second quarter. California State Teachers Retirement System now owns 51,713 shares of the company’s stock valued at $1,622,000 after buying an additional 621 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.